Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1975 1
1977 1
1980 1
1983 1
1986 2
1987 4
1988 3
1990 2
1991 1
1992 4
1993 1
1994 4
1995 5
1996 1
1997 5
1998 3
1999 6
2000 9
2001 14
2002 23
2003 17
2004 25
2005 37
2006 38
2007 41
2008 60
2009 60
2010 78
2011 96
2012 111
2013 104
2014 127
2015 152
2016 160
2017 143
2018 187
2019 189
2020 234
2021 279
2022 254
2023 212
2024 62

Text availability

Article attribute

Article type

Publication date

Search Results

2,469 results

Results by year

Filters applied: . Clear all
Page 1
Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.
Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD. Shetty R, et al. Diabetes Metab Syndr. 2022 Mar;16(3):102427. doi: 10.1016/j.dsx.2022.102427. Epub 2022 Feb 12. Diabetes Metab Syndr. 2022. PMID: 35217468 Review.
RESULTS: The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide - 46, exenatide - 46, dulaglutide - 20, semaglutide - 4, albiglutide - 2, lixisenatide - 2). The major ADRs reported was gastrointestinal disorders (n = 40) followed by renal (n = …
RESULTS: The study identified 120 cases of GLP-1 agonists associated ADRs (liraglutide - 46, exenatide - 46, dulaglutide - 20, semaglutide - …
Actin cytoskeleton remodeling primes RIG-I-like receptor activation.
Acharya D, Reis R, Volcic M, Liu G, Wang MK, Chia BS, Nchioua R, Groß R, Münch J, Kirchhoff F, Sparrer KMJ, Gack MU. Acharya D, et al. Cell. 2022 Sep 15;185(19):3588-3602.e21. doi: 10.1016/j.cell.2022.08.011. Cell. 2022. PMID: 36113429 Free PMC article.
Reply.
Lois N; of the EMERALD Study Group. Lois N, et al. Ophthalmology. 2021 Sep;128(9):e46-e47. doi: 10.1016/j.ophtha.2021.05.014. Epub 2021 Jun 25. Ophthalmology. 2021. PMID: 34183173 No abstract available.
Schistosome immunomodulators.
Acharya S, Da'dara AA, Skelly PJ. Acharya S, et al. PLoS Pathog. 2021 Dec 30;17(12):e1010064. doi: 10.1371/journal.ppat.1010064. eCollection 2021 Dec. PLoS Pathog. 2021. PMID: 34969052 Free PMC article. Review.
Evolution of the SARS-CoV-2 Omicron spike.
Parsons RJ, Acharya P. Parsons RJ, et al. Cell Rep. 2023 Dec 26;42(12):113444. doi: 10.1016/j.celrep.2023.113444. Epub 2023 Nov 18. Cell Rep. 2023. PMID: 37979169 Free PMC article. Review.
Targeting TGF-β: triumphs and challenges.
Acharya B, Miah S, Frett B. Acharya B, et al. Future Med Chem. 2022 Apr;14(7):455-458. doi: 10.4155/fmc-2021-0344. Epub 2022 Feb 13. Future Med Chem. 2022. PMID: 35152715 No abstract available.
Lipid Polarization during Cytokinesis.
Kunduri G, Acharya U, Acharya JK. Kunduri G, et al. Cells. 2022 Dec 8;11(24):3977. doi: 10.3390/cells11243977. Cells. 2022. PMID: 36552741 Free PMC article. Review.
Role of n-3 Fatty Acids on Bile Acid Metabolism and Transport in Dyslipidemia: A Review.
Acharya P, Uppin V, Zarei M, Talahalli RR. Acharya P, et al. Lipids. 2021 Mar;56(2):125-139. doi: 10.1002/lipd.12289. Epub 2020 Oct 19. Lipids. 2021. PMID: 33074554 Review.
Yet, their consumption rate is poor compared to n-6 fatty acids [linoleic acid (18:2n-6)], which are predominantly consumed. Hence, the skewed n-6 to n-3 fatty acid ratio may have a bearing on the risk factors of various diseases, including dyslipidemia. ...
Yet, their consumption rate is poor compared to n-6 fatty acids [linoleic acid (18:2n-6)], which are predominantly consumed. Hence, t …
2,469 results